【藥品性質提示】 ★LASA藥品：TRA03 【E4】Trajenta 錠劑 5mg (形似) 點擊看LASA藥品外觀比較圖

糖尿病 (DPP4I) Type 2 diabetes mellitus 第2型糖尿病

Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide(GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation.

Tmax : 1.5hour, Protein Binding: 70 – 99% (concentration dependent); Half-life elimination: Effective (therapeutic): ~12 hours; Terminal (DPP-IV saturable binding): >100 hours; Excretion: 80% feces unchanged; 5% urine unchanged

in patients with a history of a hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyper-reactivity.

B

Excretion in breast milk unknown/use caution

Hypoglycemia (combined with metformin and/or sulfonylurea [15% to 23%]; monotherapy [<1% to 7%]; metformin [<1%], pioglitazone [<1%]);Nasopharyngitis, arthralgia, back pain, headache, and hypersensitivity.

Adults: 5 mg once daily (with or without food). Children: Safety and effectiveness have not been established. In Elderly, Renal function impairment, or Hepatic function impairment patients: No dose adjustment is recommended.

No dose adjustment is recommended.

No dose adjustment is recommended.